All > Oncology > Multiple Myeloma

Anti-LAG-3 for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Multiple Myeloma+1 MoreAnti-LAG-3 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is for patients with Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone.

Eligible Conditions
  • Multiple Myeloma
  • Relapsed or Refractory Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Fluorouracil
1
Experimental
1
Ozanimod

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 18 months.

Cycle 1 (28 days)
Frequency, type and grade of Adverse Events and Serious Adverse Events
Month 18
Overall Response Rate

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Fluorouracil
1
Experimental
2
Ozanimod

Trial Design

5 Treatment Groups

Arm A - Elotuzumab
1 of 5
Arm C - Anti-TIGIT Single Agent
1 of 5
Arm B - Anti LAG-3 Single Agent
1 of 5
Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone
1 of 5
ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone
1 of 5

Active Control

Experimental Treatment

104 Total Participants · 5 Treatment Groups

Primary Treatment: Anti-LAG-3 · No Placebo Group · Phase 1 & 2

Arm C - Anti-TIGIT Single Agent
Drug
Experimental Group · 1 Intervention: Anti-TIGIT · Intervention Types: Drug
Arm B - Anti LAG-3 Single Agent
Drug
Experimental Group · 1 Intervention: Anti-LAG-3 · Intervention Types: Drug
Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone
Drug
Experimental Group · 1 Intervention: Anti-LAG-3 + Pomalidimide + Dexamethasone · Intervention Types: Drug
ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone
Drug
Experimental Group · 1 Intervention: Anti-TIGIT + Pomalidimide + Dexamethasone · Intervention Types: Drug
Arm A - Elotuzumab
Drug
ActiveComparator Group · 1 Intervention: Elotuzumab, pomalidomide, dexamethasone · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 18 months.

Who is running the clinical trial?

Multiple Myeloma Research ConsortiumLead Sponsor
18 Previous Clinical Trials
1,042 Total Patients Enrolled
17 Trials studying Multiple Myeloma
989 Patients Enrolled for Multiple Myeloma
Memorial Sloan Kettering Cancer CenterOTHER
1,833 Previous Clinical Trials
588,244 Total Patients Enrolled
75 Trials studying Multiple Myeloma
85,523 Patients Enrolled for Multiple Myeloma
Beth Israel Deaconess Medical CenterOTHER
778 Previous Clinical Trials
844,329 Total Patients Enrolled
12 Trials studying Multiple Myeloma
1,043 Patients Enrolled for Multiple Myeloma
Wake Forest University Health SciencesOTHER
1,127 Previous Clinical Trials
1,137,323 Total Patients Enrolled
18 Trials studying Multiple Myeloma
3,590 Patients Enrolled for Multiple Myeloma
University of MichiganOTHER
1,634 Previous Clinical Trials
6,415,170 Total Patients Enrolled
1 Trials studying Multiple Myeloma
660 Patients Enrolled for Multiple Myeloma
Icahn School of Medicine at Mount SinaiOTHER
781 Previous Clinical Trials
483,791 Total Patients Enrolled
7 Trials studying Multiple Myeloma
1,182 Patients Enrolled for Multiple Myeloma
Dana-Farber Cancer InstituteOTHER
1,017 Previous Clinical Trials
393,724 Total Patients Enrolled
50 Trials studying Multiple Myeloma
34,321 Patients Enrolled for Multiple Myeloma
Emory UniversityOTHER
1,509 Previous Clinical Trials
2,705,902 Total Patients Enrolled
24 Trials studying Multiple Myeloma
1,874 Patients Enrolled for Multiple Myeloma
University of TexasOTHER
173 Previous Clinical Trials
121,737 Total Patients Enrolled
Hackensack Meridian HealthOTHER
114 Previous Clinical Trials
24,681 Total Patients Enrolled
19 Trials studying Multiple Myeloma
1,307 Patients Enrolled for Multiple Myeloma
Washington University School of MedicineOTHER
1,805 Previous Clinical Trials
2,278,511 Total Patients Enrolled
27 Trials studying Multiple Myeloma
1,082 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbIndustry Sponsor
2,501 Previous Clinical Trials
3,928,122 Total Patients Enrolled
72 Trials studying Multiple Myeloma
14,241 Patients Enrolled for Multiple Myeloma
Daniel Auclair, Ph.D.Principal InvestigatorChief Scientific Officer
1 Previous Clinical Trials
228 Total Patients Enrolled
1 Trials studying Multiple Myeloma
228 Patients Enrolled for Multiple Myeloma
Madhav V. Dhodapkar, M.D.Principal InvestigatorMedical Monitor
Hearn J. Cho, M.D., Ph.D.Principal InvestigatorChief Medical Officer

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Creatinine clearance ≥ 30 mL/min by Cockcroft Gault Equation.
The monoclonal protein in serum is ≥1.0 g.
You are eligible for this study if you are 18 years of age or older.
ANC > 1000/ul (without growth factor support within 14 days of initiation of therapy).
Total bilirubin is >1.5 x ULN or if total bilirubin is ≥1.5 x ULN, the direct bilirubin must be ≤ 2.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top